ASP8062 + Placebo ASP8062 + buprenorphine/naloxone
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid Use Disorder
Conditions
Opioid Use Disorder
Trial Timeline
Jun 29, 2020 โ Nov 25, 2020
NCT ID
NCT04447287About ASP8062 + Placebo ASP8062 + buprenorphine/naloxone
ASP8062 + Placebo ASP8062 + buprenorphine/naloxone is a phase 1 stage product being developed by Astellas Pharma for Opioid Use Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04447287. Target conditions include Opioid Use Disorder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05062577 | Phase 2 | Withdrawn |
| NCT04447287 | Phase 1 | Completed |
Competing Products
20 competing products in Opioid Use Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| ASP8082 + morphine + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP8062 + Placebo ASP8062 + buprenorphine/naloxone | Astellas Pharma | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Approved | 85 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Phase 2 | 52 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| naloxegol + non-PAMORA laxative | Kyowa Kirin | Pre-clinical | 23 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| Brenipatide + Placebo + Buprenorphine | Eli Lilly | Phase 2 | 52 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| Naloxegol + Naloxegol | AstraZeneca | Phase 1 | 33 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |
| Polyethylene Glycol 3350 + Movantik | AstraZeneca | Approved | 85 |